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Abstract
Background: To analyse the outcome of elderly patients (≥70 years) with esophageal cancer treated with curative
intent radio(chemo)therapy.
Methods: Fifty five patients (median 75 years) receiving curative intent radio(chemo)therapy for esophageal
cancer from 1999 to 2015 were retrospectively analyzed. Most patients showed locally advanced disease (T3/4:78%,
N+:58%) with squamous cell histology (74%). Charlson comorbidity score was > 1 in 27%. 48 patients (87%)
received definitive treatment while 7 patients were treated neoadjuvantly. RT was carried out as 3D-conformal
treatment or IMRT. Concurrent chemotherapy was applied in 85%, mainly cisplatin/5-FU or mitomycin/5-FU.
18FDG-PET/CT staging was used in 65%.
Results: Median follow-up was 11 months (1–68) and 21 months in survivors. 1- and 2-year rates of LRC, DC, FFTF
and OS were 60%/45, 81%/72, 55%/41 and 46%/26% for the entire cohort. In univariate analysis, addition of surgery
was associated with improved LRC and FFTF, nodal involvement with improved DC and lower T stage, lower
Charlson score and use of PET-CT with improved OS. In multivariate analysis, lower T stage and lower Charlson
score remained significant for OS. Patients treated after 2008 showed a significantly improved FFTF (1-year FFTF
64% vs 35%) and OS (1-year OS 66% vs 24%). Maximum (chemo)radiation related grade3+ toxicity was observed
in 80% including 7 deaths (13%). Grade5 toxicity was significantly associated with Charlson score (CS > 1:33% vs
CS ≤ 1:5%) and treatment period (24% before vs 3% after 2008). The patients treated after 2008 included
significantly more SCCs, less T4 stages, had a higher percentage of PET-CT staging and were treated with smaller
field lengths. Trends were also observed for lower Charlson scores and increased use of IMRT.
Conclusion: Curative intent (chemo)radiation of elderly patients with esophageal cancer may result in considerable
toxicity and unfavorable outcome. However, a clear improvement over time was observed in our cohort, probably
based on improved patient selection. In patients with less advanced stages and lower comorbidity similar results as
in younger cohorts seem achievable with modern staging and treatment approaches. Age per se should not be a
decisive factor, but careful attention should be paid regarding patient selection including a structured and tight
follow-up strategy.
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Background
The overall life expectancy in western countries has im-
proved over the last decades while the incidence for can-
cer has increased. Therefore the management of elderly
cancer patients will become a major challenge in the fu-
ture. For esophageal cancer a rising incidence worldwide
has been reported [1] with a considerable change in the
morphologic appearance of the tumors. To date, squa-
mous cell carcinomas still account for the majority of
esophageal cancers in western countries, however in re-
cent years the incidence of adenocarcinomas has increased
notably [2]. Multimodality treatment is considered stand-
ard of care in the treatment of patients with locally ad-
vanced esophageal cancer based on the encouraging
evidence that in potentially curable disease preoperative
chemoradiotherapy (CRT) can improve survival of pa-
tients with esophageal or esophagogastric-junction (GEJ)
cancer [3] compared to surgery alone. In case of non-
resectable tumors, definitive CRT may result in 5-year sur-
vival rates of approximately 20% [4]. The addition of sur-
gery to CRT has shown to improve local control but not
survival in locally advanced esophageal cancer [5]. How-
ever, elderly patients are often excluded or at least under-
represented in randomized trials, thus questioning the
general transferability of their results into the elderly
population [6, 7]. For example, the upper age limit for eli-
gibility in the mentioned CROSS trial was 75 years and
the mean age of the included patients was 60 years. While
it may be true that some elderly patients are not suitable
for multimodality treatment, age per se may not be a good
parameter for treatment decisions. However, a recent
SEER-analysis on elderly esophageal cancer patients re-
ported a distinct underutilization of treatment in patients
aged > 65 years, despite showing a significant survival
benefit for patients with treatment vs best supportive care
[8]. Further on, increased age did not significantly influ-
ence overall outcome or the complication rate in patients
treated with extended esophagectomy according to a re-
cent analysis by Pultrum et al. [9]. In contrast, the pres-
ence of comorbidity had a significant impact on survival,
indicating that comorbidity and/or performance status
seem to be more suitable factors for decision making than
chronologic age per se. To our knowledge, no high-
level evidence specifically addressing the outcome of
elderly patients treated by radiation-containing curative
intent approaches has been published so far. Here we
present a retrospective analysis of our experience
including an evaluation of possible factors affecting
outcome and toxicity.
Methods
We performed a retrospective analysis of 55 patients
aged ≥70 years with esophageal cancer who were treated
with neoadjuvant or definitive RT with or without
concomitant chemotherapy at our institution between
11/1999 and 01/2014. Inclusion criteria were newly diag-
nosed histologically proven squamous cell or adenocar-
cinoma of the esophagus, age ≥ 70 years at start of
therapy and neoadjuvant or definitive RT using 3D-
conformal or intensity-modulated RT techniques.
Patients were excluded if they had distant metastases
other than celiac or supraclavicular lymph nodes, were
treated for recurrent disease or received 2-dimensional ra-
diation therapy. Median age was 75 years (range 70–85),
45 patients were male, 10 were female. The majority of pa-
tients received definitive RT or CRT, 7 patients received
surgery after neoadjuvant CRT. A systematic review of pa-
tients’ clinical charts and reports was performed to obtain
patient and treatment characteristics, reported toxicity,
and treatment outcome. For the purpose of this study, all
patients were restaged according to the 7th edition of the
UICC TNM classification. For detailed patient and treat-
ment characteristics see Table 1.
Initial work-up
Initial work-up included at least clinical and laboratory
examinations, endoscopy with biopsy and computed
tomography of the chest and abdominal ultrasound. 36
patients received 18FDG positron emission tomography
(PET/CT) imaging prior to radiation therapy.
(chemo)-radiation therapy
Due to the long time period covered by this study, target
delineation, radiation technique and dose prescription
varied to some extent. Usually patients were treated in
supine position using an alpha-cradle. The gross tumor
volume (GTV) included the primary tumor and involved
lymph nodes. In general, the primary CTV covered at
least 5 cm in both directions along the longitudinal axis
from the primary tumor and at least 1 cm of uninvolved
mediastinal soft tissue in axial direction excluding adja-
cent lung tissue in the sense of an elective nodal irradi-
ation. An isotropic margin of 0.5–1 cm was added to
receive the PTV. Primary tumor and lymph node
delineation was further supported by PET-CT if available
(n = 36). Radiation therapy was administered in multiple
field techniques either as 3D-conformal RT (n = 50, 91%)
or IMRT (n = 5, 9%) with an intended dose of 50.4 Gy in
conventional fractionation. For definitive treatment a se-
quential boost of 9 Gy to the GTV plus 2 cm in longitu-
dinal direction and 1 cm in axial direction was usually
added. Patient treated with IMRT received a similar
dose prescription using an integrated boost concept.
Patients were scheduled for simultaneous chemother-
apy (n = 47, 85%) or radiation alone (n = 8, 15%) based
on performance status, comorbidity and presence of
specific contraindications regarding the planned sub-
stances by the treating radiation oncologist. In the
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majority of patients, chemotherapy consisted either of
two courses of cisplatin/5-fluorouracil (cisplatin
75 mg/m2 body-surface area on the first day com-
bined with 5-fluorouracil 1000 mg/m2 continuous
infusion daily for four days) or two courses of mitomycin
C/5-fluorouracil (mitomycin C 10 mg/m2 day one, 5-
fluorouracil 1000 mg/m2 first 5 days).
Follow-up
Follow-up took place at our institution or at the refer-
ring center and included at least clinical examination
and endoscopy. In case of clinical evidence for loco-
regional recurrence or distant spread, additional tests or
imaging modalities were performed to confirm or ex-
clude disease progression at the discretion of the treating
physician. Since 2008, all patients were offered a struc-
tured follow-up at our institution including at least clin-
ical examination, endoscopy and CT chest every three
months for the first two years and in 6–12 month inter-
vals thereafter. Patients and their primary care physi-
cians (via treatment report) were encouraged to report
complications after chemoradiation promptly to our
center and were contacted via phone in case of missing
a scheduled follow-up visit.
Statistical and ethical considerations
All time to event data was calculated from the date of
first radiation treatment until last follow-up information
or until death using the Kaplan-Meier method. Locore-
gional control (LRC) was defined as absence of disease
progression in the primary tumor region or regional
lymph nodes. Distant control (DC) was defined as ab-
sence of distant failure. Freedom from treatment failure
(FFTF) was defined as absence of locoregional and dis-
tant failure. Differences between subgroups regarding
time to event data were compared using a log rank test
for univariate analysis. Parameters with p < 0.1 in univar-
iate analysis were entered into a Cox regression model
for multivariate analysis. Differences in patient- or treat-
ment related parameters between subgroups defined by
treatment period were analyzed using the chi-square or
fisher’s exact test for categorial and the t-test for con-
tinuous variables. A p-value of < 0.05 was defined as sta-
tistically significant. Acute and late toxicity was scored
retrospectively according to CTCAEV4.03. Comorbidity
was scored according to the Charlson score. Histopatho-
logical regression in resected patients was graded ac-
cording to Baldus et al. [10]. The study was performed
in accordance to the declaration of Helsinki in its latest
version and was approved by our independent ethics
committee. All patients gave written informed consent
prior to treatment initiation.
Results
Median follow up for the entire cohort was 11 months
(1–68) and 21 months in survivors. Radiotherapy was
completed as planned without interruptions ≥4 days in
47 patients (85%). In patients scheduled for combined
CRT, 66% received full course chemotherapy and 77%
received at least 80% of the planned chemotherapy dose.
Surgery and pathologic response
Seven patients were treated neoadjuvantly and received
surgery. Of these, one suffered from adenocarcinoma
and six from squamous cell carcinoma. Margin status
was available in 5 patients and was microscopically
complete in all of them. Response status according to
imaging was complete remission in one, partial remis-
sion in 4 and stable disease in 1. Histopathological re-
gression grading was available in 5 patients and resulted
in grade 2 in 2 patients, grade 3 in 1 patient and grade 4
(pathologically complete remission) in 2 patients.
Table 1 Patient and treatment characteristics (n)
Gender Time period
Male 45 Before 2008 25
Female 10 After 2008 30
Age PET-CT Staging
Median 75 yrs Yes 36
Range 70–85 yrs No 19
Charlson Comorbidity Index RT sequence
≤1 40 Definitive 48
> 1 15 Neoadjuvant 7
Histology RT technique
Adenocarcinoma 14 3D-CRT 50
SCC 41 IMRT 5
Localization RT dose
Cervical 5 median 59.4Gy
Upper thoracic 12 range 10.8-66Gy
Middle thoracic 20
Lower thoracic 18 Chemotherapy
Yes 47
Grading full course 31
G1 1 > 80% 36
G2 30 < 80% 11
G3 24 None 8
T stage N stage
T1 1 N0 23
T2 11 N+ 32
T3 32
T4 11
yrs years, SCC squamous cell carcinoma, PET-CT positron emission tomography
with computed tomography, RT radiation therapy, 3D-CRT three-dimensional
conformal radiation therapy, IMRT intensity modulated radiation therapy
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Outcome
Locoregional recurrences were observed in 19 patients,
translating into estimated 1- and 2-year LRC rates of 60
and 45% (Fig. 1). Of these 14 were only local, two were
only nodal and three were combined. The median time to
the onset of a locoregional recurrence was 7 months. In
univariate analysis only the addition of surgery resulted in
significantly improved locoregional control (1-year LRC
100% vs. 53%, 2-year LRC 100% vs. 34%, p = 0.02, Fig. 2). A
trend for improved locoregional control was found in pa-
tients treated in the recent time period (after 2008) (1-year
LRC 67% vs. 42%, 2-year LRC 58% vs. 14%, p = 0.06, Fig. 3)
and for patients staged with PET-CT (1-year LRC 66% vs.
27%, 2-year LRC 54% vs. 0%, p = 0.085), see Table 2.
Distant metastases were observed in 10 patients,
mainly to the lung (n = 7), translating into estimated 1-
and 2-year DC rates of 81 and 72% (Fig. 1). The median
time to the onset of distant failure was 8 months. In uni-
variate analysis, nodal involvement was the only signifi-
cant predictor of distant failure (1-year DC 93% vs. 72%,
2-year DC 93% vs. 58%, p = 0.04, Fig. 2), while a trend to
improved DC was observed in patients with the achieve-
ment of locoregional control (1-year DC 87% vs. 72%, 2-
year DC 87% vs. 51%, p = 0.054), see Table 2.
Disease progression in general was found in 22 pa-
tients, translating into estimated 1- and 2-year FFTF
rates of 55 and 41% (Fig. 1). Of these, 12 were isolated
locoregional, 3 were isolated distant and 7 were
combined. In univariate analysis, the addition of surgery
(1-year FFTF 47% vs. 100% and 2-year FFTF 31% vs.
100%, p = 0.02, Fig. 2) and treatment in the latter time
period (1-year FFTF 35% vs. 64%, 2-year FFTF 12% vs
55%, p = 0.048, Fig. 3) resulted in significantly improved
FFTF (Table 2).
a. b.
c. d.
Fig. 1 LRC, DC, FFTF, OS for the entire cohort
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a. b.
c. d.
e. f.
Fig. 2 prognostic factors for LRC, DC, FFTF and OS according to univariate analysis
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At time of analysis, 43 patients had died (78%),
translating into a median overall survival of 12 months
with estimated 1- and 2-year OS rates of 46 and 26%
(Fig. 1). In univariate analysis, OS was significantly
associated with T stage (1-year OS T1–3: 56% vs T4:
9%, p = 0.002, Fig. 2), comorbidity (1-year OS CS ≤1:
51% vs. CS > 1: 33%, p = 0.04, Fig. 2), treatment
period (1-year OS prior 2008: 24% vs after 2008: 66%,
p < 0.001, Fig. 3) and the use of PET-CT for staging
(1-year OS 63% vs 17%, p < 0.001, Fig. 2). A trend
was found for the addition of surgery (1-year OS 71%
vs 43%, 2-year OS 57% vs 20%, p = 0.055) and the
use of IMRT (1-year OS 80% vs 43%, p = 0.076), see
Table 2.
In multivariate analysis none of the tested factors was
significant for LRC, DC or FFTF. However for overall
survival T stage (p = 0.029, HR 2.97, KI 1.12–7.92) and
comorbidity (p = 0.007, HR 2.93, KI 1.33–6.42) remained
significant in the multivariate analysis.
Toxicity
Maximum acute toxicity during or after (chemo)radi-
ation therapy was grade 3 in 31 patients (56%), grade 4
in 6 (11%) and grade 5 in 7 (13%), mainly dysphagia, in-
fections and leukopenia. For detailed analysis of acute
toxicity see Table 3. Three patients died during hospital
admission for CRT (2 sepsis, 1 hemorrhage) and four pa-
tients died after CRT was finished and they had been
discharged (3 pneumonia, 1 sepsis). None of these four
patients had been readmitted to our center for complica-
tion management. Grade 5 toxicity correlated signifi-
cantly with treatment period (24% before 2008 vs. 3%
a. b.
c. d.
Fig. 3 LRC, DC, FFTF, OS according to treatment period (before vs after 2008)
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Table 2 Univariate analysis of prognostic factors
LRC DC FFTF OS
1-yr rate p value 1-yr rate p value 1-yr rate p value 1-yr rate p value
Gender
Male 63% 0.192 81% 0.464 57% 0.33 43% 0.443
Female 44% 78% 44% 60%
Age
< 75 yrs 54% 0.523 78% 0.572 50% 0.652 30% 0.236
≥ 75 yrs 63% 80% 57% 58%
Charlson score
≤ 1 61% 0.901 83 0.493 58% 0.991 51% 0.041
> 1 56% 74 55% 33%
Histology
SCC 62% 0.484 86% 0.121 57% 0.456 50% 0.107
Adenocarcinoma 55% 63% 47% 36%
Localization
Cervical 80% 0.335 80% 0.427 60% 0.267 60% 0.249
Upper thoracic 71% 100% 71% 33%
Middle thoracic 51% 76% 47% 47%
Lower thoracic 59% 77% 53% 61%
Grading
G2 63% 0.853 80% 0.811 57% 0.818 53% 0.238
G3 53% 79% 48% 39%
T stage
T1–3 59% 0.911 83% 0.374 55% 0.559 56% 0.002
T4 78% 78% 67% 9%
N stage
N0 70% 0.201 93% 0.035 64% 0.161 44% 0.921
N+ 54% 72% 49% 48%
time period
before 2008 42% 0.061 84% 0.366 35% 0.048 24% < 0.001
after 2008 67% 80% 64% 66%
PET-CT Staging
yes 66% 0.085 80% 0.866 61% 0.101 63% < 0.001
no 27% 86% 25% 17%
RT sequence
neoadj 100% 0.022 100% 0.146 100% 0.014 71% 0.055
definitive 53% 77% 47% 43%
RT technique
3D-CRT 59% 0.638 83% 0.918 53% 0.508 43% 0.076
IMRT 75% 75% 75% 80%
Chemotherapy
no 30% 0.351 86% 0.481 28% 0.24 50% 0.317
yes 64% 80% 61% 46%
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after 2008, p = 0.039) and comorbidity (33% with Charlson
score > 1 vs. 5% with Charlson score ≤ 1, p = 0.013). Of the
7 patients who received additional surgery, two developed
grade 4 postoperative complications (sepsis). 30-day
mortality was 14% (1 patient died intraoperatively due to
cardiac failure).
Late toxicity in terms of dysphagia with the need for
intervention was observed in 13 patients. Of those one
was long-term PEG dependent, 12 needed dilatations
(median 2, range 1–6) and one stent placement. No
cases of severe pulmonary or cardiac late toxicity were
observed.
Treatment period
We analyzed our cohort with regard to different treat-
ment periods to evaluate if outcome has improved over
time. Because of the implementation of a structured
follow-up in 2008, we splitted the cohort in subgroups
treated before and after 2008. Patients treated in the
recent time period (since 2008) showed improved
outcome with regard to 1-year LRC (42% vs. 67%), DC
(80% vs. 84%y), FFTF (35% vs. 64%y) and OS (24% vs.
66%y), with the difference in FFTF and OS reaching
statistical significance (Fig. 3, Table 2). We therefore
evaluated possible differences regarding patient and
treatment related factors between those groups. They
differed significantly with regard to histology (56% vs
90% SCC, p = 0.04), T stage 4 (32% vs 10%, p = 0.042),
number of patients receiving PET-CT for treatment
planning (25% vs 100%, p < 0.001) and maximum
cranio-caudal extension of the PTV (mean 21.6 cm vs
19.0 cm, p = 0.017). Trends were found for Charlson
score ≤ 1 (60% vs 83, p = 0.053) and the use of IMRT
(0% vs. 17%, p = 0.056), see Table 4. As mentioned be-
fore, also grade 5 toxicity correlated significantly with
treatment period (24% vs. 3%, p = 0.039).
Discussion
The treatment of locally advanced non-metastasized
esophageal cancer usually consists of surgery, chemoradia-
tion or combinations of both [11]. Efficacy and tolerability
of definitive concurrent chemoradiation and its benefits in
terms of survival compared to radiation alone have been
established by randomized trials already in the 1990s [12].
More recently preoperative CRT has been shown to im-
prove survival of patients with potentially curable esopha-
geal or GEJ-cancer [3] compared to surgery alone.
However, elderly patients are generally underrepresented
or even excluded from such trials [6, 13] resulting in less
high-level evidence regarding their appropriate treatment.
Combined with other factors (like the (mis)-conception of
decreased treatment tolerance per se, multiple comorbidi-
ties or socioeconomic problems), this uncertainty may re-
sult in considerable undertreatment with reduced survival
as recently shown by Molena et al. [8].
In our study we analyzed 55 patients treated mainly
with definitive or (to a lesser extent) neoadjuvant
(chemo)radiation, which are both widely accepted as
curative intent treatment options. With this approach
we observed a median survival of 12 months with 2-year
LC and OS rates of 45 and 26%. These results compare
less favorable with large randomized studies including
younger populations, which report a median survival of
12–19 months with 2-year LRC rates of 41–57% and 2-
year-OS rates of 28–40% using similar definitive chemo-
radiation schemes [5, 12, 14, 15]. The SCOPE1 trial
Table 2 Univariate analysis of prognostic factors (Continued)
LRC DC FFTF OS
1-yr rate p value 1-yr rate p value 1-yr rate p value 1-yr rate p value
LRC
no 87% 0.054 37% 0.605
yes 72% 63%
LRC locoregional control, DC distant control, FFTF freedom from treatment failure, OS overall survival, 1-yr rate 1-year rate, yrs. years, PET-CT positron emission
tomography with computed tomography, RT radiation therapy, 3D-CRT three-dimensional conformal radiation therapy, IMRT intensity-modulated radiation therapy
Table 3 acute toxicities
All grades Grade 3–5
n % n %
non-hematological
skin 16 29 0 0
mucositis 23 42 2 4
dysphagia 52 95 32 58
nausea 11 20 1 2
vomiting 4 7 1 2
diarrhea 5 9 0 0
weight loss 10 18 0 0
hoarsness 10 18 0 0
bleeding 1 2 1 2
others 7 9 5 9
hematological
anemia 50 91 3 5
leucopenia 46 84 18 33
thrombopenia 36 65 4 7
infection 20 36 16 29
renal insufficiency 13 24 0 0
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recently reported even much more favourable outcomes
in their standard arm using definitive chemoradiation
leading to a median OS of 25 months with a 2-year OS
rate of 56% [16]. In contrast, a population-based study
from the Netherlands including patients from four refer-
ral centers treated by radio(chemo)therapy observed very
similar results with a median survival of 11 months and
2-year LRC and OS rates of 45 and 22%, respectively
[17], indicating that results generated in the general
population may vary distinctly from outcomes in
controlled trials. Several other groups have specifically
evaluated the outcome of elderly patients with esopha-
geal cancer treated with chemoradiation. They observed
median OS times of 13–19 months and 2-year OS rates
of 27–43% in more or less selected patient cohorts
[18–24]. Servagi-Vernat et al. [24] performed the only
prospective phase II trial and found a 3-year OS of 22%
in patients aged ≥75 years treated with chemoradiation
consisting of 50 Gy and single-agent cisplatin or oxali-
platin, respectively. Vlacich et al. [25] reported a na-
tional cancer database (NCDB) analysis focusing on
treatment utilization and outcome in patients aged
≥70 years and reported a 2-year OS rate of roughly 35%
for patients treated by chemoradiation. Regarding the
influence of age per se, conflicting results have been de-
scribed in series directly comparing elderly patients
with younger ones. For example, Vonken et al. [26]
compared 76 patients aged ≥70 yrs. with 176 patients
aged < 70 years treated either by neoadjuvant or defini-
tive chemoradiation and found no significant difference
in overall survival. In contrast, Takeuchi et al. [20] re-
ported on 33 patients aged > 71 years and 145 patients
aged < 70 years treated with definitive chemoradiation
and observed a clearly inferior median survival in the
elderly group (median OS 14.7 vs 35.1 months). Inter-
estingly, both series reported lower treatment compli-
ance (more chemotherapy dose reductions and/or
discontinuations) and Takeuchi et al. [20] found an in-
creased toxicity in the elderly group. We also observed
considerable toxicity in our series including treatment-
related deaths in 7 patients, which mainly occurred
after patients had been discharged from hospital after
treatment was finished. Overall survival and grade 5
toxicities were significantly associated with a Charlson
score > 1, indicating that comorbidity may play a more
important role than age per se. Tougeron et al. [22]
similarly described a significant association of comor-
bidity with treatment tolerance and overall survival in
their series of 109 patients aged ≥70 treated with definitive
chemoradiation. In the prior mentioned NCDB analysis,
only 5% of the patients had a Charlson score > 1 compared
to 27% in our study, which may have contributed to the
favourable results [25]. Similarly, in the SCOPE1 trial only
15% of the patients included received definitive
Table 4 Treatment period
Before 2008 After 2008
n % n % p-value
Gender
male 22 88 23 77 0.318
female 3 12 7 23
Age
<median (75 yrs) 8 32 15 50 0.178
≥median 17 68 15 50
Charlson score
≤ 1 15 60 25 83 0.053
> 1 10 40 5 17
Histology
SCC 14 56 27 90 0.04
Adenocarcinoma 11 44 3 10
Localization
Cervical 2 8 3 10 0.964
Upper thoracic 5 20 7 23
Middle throacic 9 36 11 37
Lower thoracic 9 36 9 30
Grading
G2 13 52 17 57 0.580
G3 12 48 12 40
T stage
T1–3 17 68 27 90 0.042
T4 8 32 3 10
N stage
N0 11 44 12 40 0.765
N+ 14 56 18 60
PET-CT Staging
yes 6 24 30 100 < 0.001
no 19 76 0 0
RT sequence
Neoadjuvant 1 4 6 20 0.112
Definitive 24 96 24 80
RT technique
3D-CRT 25 100 25 83 0.056
IMRT 0 0 5 17
Chemotherapy
yes 19 76 28 93 0.123
no 6 24 2 7
Treatment field
< 20 cm 7 28 18 60 0.033
≥ 20 cm 16 64 12 40
yrs years, SCC squamous cell carcinoma, PET-CT positron emission
tomography with computed tomography, RT radiation therapy,
3D-CRT three-dimensional conformal radiation therapy,
IMRT intensity-modulated radiation therapy, cm centimeters
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chemoradiation due to comorbidities and all had good
performance status [16]. Regarding specific comorbidities
we did not observe a significant correlation to outcome or
grade 5 toxicity, although patients with grade 5 toxicity
showed more often cardiovascular comorbidities (57% vs
38%, data not shown). Interestingly, we found large differ-
ences in overall outcome and toxicity if patients were
stratified according to treatment period. Patient who re-
ceived treatment after 2008 had a clearly improved out-
come with a 1-year LRC and OS rates of 67 and 66%
compared to 42 and 24% if treatment started before 2008.
Moreover, grade 5 toxicity dropped from 24 to 3%. Com-
paring the subgroups according to treatment period we
observed significantly less advanced T stages (T4 10% vs.
32%) and adenocarcinomas (10% vs. 44%), a significantly
increased percentage of patients staged with PET-CT
(100% vs. 25%) and a significantly reduced craniocaudal
extension of the PTV in recently treated patients. Trends
were also observed for the increasing use of IMRT and a
lower Charlson score. High T stage is well known to be as-
sociated with decreased survival as shown by others [18,
27, 28] and was also identified as a negative prognostic for
OS in our series according to multivariate analysis. Re-
garding histology, a clear impact on overall survival as not
been established so far. While a recent population-based
analysis [17] found a significantly decreased 2-year sur-
vival in patients with adenocarcinoma compared to SCC
(17% vs 29%) after definitive CRT or RT, a large retro-
spective cohort analysis for patient treated with chemora-
diation could only confirm an increased risk for distant
metastases but did not observe a difference in overall sur-
vival [29]. Charlson score has also been shown to be asso-
ciated with overall survival as well as with grade 5 toxicity
in our series. Similarly, Tougeron et al. [22] observed a
significant impact of Charlson score on treatment toler-
ance, high grade adverse effects and overall survival in
their series of elderly patient treated with chemoradiation.
Taken together, it seems that a better selection of patients
has contributed to the clearly improved outcome in the
latter time period. This selection process may have been
supported by the increased utilization of PET-CT for sta-
ging prior to treatment initiation (100% vs. 25%), which
was associated with improved survival in our series ac-
cording to univariate analysis although not confirmed in
multivariate analysis. Similarly, Metzger et al. [30] recently
described an association of PET-CT use with improved
local-recurrence free survival and overall survival in their
series of 145 patients treated with definitive or neoadju-
vant chemoradiation. Treatment-related parameters like
modern radiation techniques (IMRT), smaller field length
and a more structured follow-up strategy may also have
contributed to improved outcome and reduced high grade
toxicity in the recently treated patients, although we could
not confirm a significant impact of one of those factors
independently in our analysis. However, several groups
have shown not only dosimetric advantages but also re-
duced toxicity and sometimes even improved locoregional
control and survival with IMRT compared to 3D—con-
formal approaches [31–33]. A reduction of field length in
terms of “involved field irradiation (IFI)” instead of “elect-
ive nodal irradiation (ENI)” has been a matter a debate for
nearly a decade because of its suggested reduction in tox-
icity. A recent meta-analysis confirmed a significant re-
duction of toxicity and observed no significant differences
in local control or survival with reduced target volumes
[34]. Moreover, Jing et al. [35] observed a reduction in
toxicity but no difference in OS comparing IFI with ENI
in a cohort of patients aged ≥70 years and concluded that
IFI should be preferred especially in elderly patients.
Taken together, our clearly superior results in the latter
time period seemed to be based on a combination of im-
proved patient selection and an adaption of treatment to-
wards less toxic approaches. Interestingly, an indirect
comparison of more recent and older prospective trials in
unselected patients leads to a similar direction. For ex-
ample the standard arm of the SCOPE1 trial (started in
2008) reported much better median OS (25 months) and
2-year OS (56%) compared to the standard arm of RTOG
8501 (recruiting patients in the late 80s) with a median
OS 12.5 months and a 2-year OS of 38%, although the
chemoradiation regimen used in both arms was similar at
least regarding radiation dose and chemotherapy drugs
[12, 16]. We also observed a nearby doubled median over-
all survival comparing our patients from the recent and
the previous time period indicating that probably a com-
bination of several advances including patient selection,
radiation technique, field design and supportive care may
have contributed to the improvement over time. With re-
spect to those boundaries, similar results can be achieved
in elderly patients regarding toxicity and outcome com-
pared to unselected cohorts as shown by the results in our
recently treated patient group.
Of course our study has some limitations, namely its
retrospective nature, small sample size, short follow-up
and inhomogeneous patient and treatment characteris-
tics. However, in the absence of randomized trials specif-
ically addressing the value of chemoradiation in elderly
patient cohorts we feel that it adds valuable information
to the existing body of literature.
Conclusion
In summary, curative intent treatment of elderly patients
with definitive or neoadjuvant chemoradiation may re-
sult in considerable toxicity and less favorable outcome.
Despite the disappointing results regarding the entire
cohort, we observed a clear improvement with increased
survival and reduced toxicity over time, mainly based on
patient selection and treatment adaptions. In patients
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with less advanced disease stage and lower comorbidity,
which are staged and treated with modern techniques and
concepts, similar results compared to younger cohorts
seem to be achievable. Therefore age per se should not be
a decisive factor in treatment decisions in esophageal
cancer although careful attention has to be paid regarding
patient selection for potentially curative treatments in-
cluding a structured and tight follow-up strategy.
Funding
The study did not receive any funding.
Availability of data and materials
The datasets used and/or analysed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
FW participated in patient treatment, data acquisition, statistical analysis and
in drafting the manuscript. DB performed data acquisition and participated
in statistical analysis. RK participated in data acquisition. NS, SB, MA, CB
participated in data acquisition, patient treatment and critically reviewed the
manuscript. FR participated in data acquisition, statistical analysis, treatment
of the patients, drafting the manuscript and critically reviewed the data and
the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
The study was approved by the Ethics committee of the University of
Munich (LMU), reference number 634–16.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Radiation Oncology, University Hospital LMU Munich,
Marchioninistr 15, 81377 Munich, Germany. 2Department of Internal
Medicine III, University Hospital LMU Munich, Marchioninistr, 15, 81377
Munich, Germany. 3Department of Surgery, University Hospital LMU Munich,
Marchioninistr, 15, 81377 Munich, Germany. 4Department of Molecular
Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg,
Germany.
Received: 19 February 2018 Accepted: 2 May 2018
References
1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241–52.
2. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of
oesophageal cancer by histological subtype in 2012. Gut. 2015;64:381–7.
3. Hagen V, Hulshof MC, van Lanschot JJ, et al. Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J Med.
2012;366:2074–84.
4. Stahl M, Budach W. Definitive chemoradiotherapy. J Thorac Dis. 2017;
9(suppl 8):S792–8.
5. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without
surgery in patients with locally advanced squamous cell carcinoma of the
esophagus. J Clin Oncol. 2005;23:2310–7.
6. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65
years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.
7. Andrä C, Klein A, Dürr HR, et al. External-beam radiation therapy combined
with limb-sparing surgery in elderly patients (>70 years) with primary soft
tissue sarcomas of the extremities: a retrospective analysis. Strahlenther
Onkol. 2017;193:604–11.
8. Molena D, Stem M, Blackford AL, Lidor AO. Esophageal cancer treatment is
underutilized among elderly patients in the USA. J Gastrointest Surg. 2017;
21:126–36.
9. Pultrum BB, Bosch DJ, Nijsten MW, et al. Extended esophagectomy in
elderly patients with esophageal cancer: minor effect of age alone in
determining the postoperative course and survival. Ann Surg Oncol. 2010;
17:1572–80.
10. Baldus SE, Mönig SP, Schröder W, et al. Regression of oesophageal
carcinomas after neoadjuvant radiochemotherapy: criteria of the
histopathological evaluation. Pathologe. 2004;25:421–7.
11. Hulshof MC, van Laarhoven HW. Chemoradiotherapy in tumours of the
oesophagus and gastro-oesophageal junction. Best Prac Res Clin
Gastroenterol. 2016;30:551–63.
12. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and
radiotherapy compared with radiotherapy alone in patients with cancer of
the esophagus. N Engl J Med. 1992;326:1593–8.
13. Scher KS, Hurria A. Under-representation of older adults in cancer registration
trials: known problem, little progress. J Clin Oncol. 2012;30:2036–8.
14. Minsky BD, Pajak TF, Ginsberg RK, et al. INT 0123 (radiation therapy
oncology group 94-05) phase III trial of combined-modality therapy for
esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin
Oncol. 2002;20:1167–74.
15. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery
compared with chemoradiation alone in squamous cancer of the
esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160–8.
16. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without
cetuximab in patients with oesophageal cancer (SCOPE1): a multicenter,
phase 2/3 randomised trial. Lancet Oncol. 2013;14:627–37.
17. Smit JK, Mujis CT, Burgerhof JG, et al. Survival after definitive
(chemo)radiotherapy in esophageal cancer patients: a population-based
study in the north-East Netherlands. Ann Surg Oncol. 2013;20:1985–92.
18. Zhao L, Zhou Y, Pan H, et al. Radiotherapy alone or concurrent
chemoradiation for esophageal squamous cell carcinoma in elderly patients.
J Cancer. 2017;8:3242–50.
19. Münch S, Heinrich C, Habermehl D, et al. Primary radio(chemo)therapy for
esophageal cacer in elderly patients: are efficiency and toxicity comparable
with younger patients? Eur J Med Res. 2017;22:24.
20. Takeuchi S, Ohtsu A, Doi T, et al. A retrospective study of definitive
chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin
Oncol. 2007;30:607–11.
21. Li X, Zhao LJ, Liu NB, et al. Feasibility and efficacy of concurrent
chemoradiotherapy in elderly patients with esophageal squamous cell
carcinoma: a retrospective study of 116 cases from a single institution. Asian
Pac J Cancer Prev. 2015;16:1463–9.
22. Tougeron D, di Fiore F, Thureau S, et al. Safety and outcome of definitive
chemoradiotherapy in elderly patients with oesophageal cancer. Br J
Cancer. 2008;99:1586–92.
23. Qu X, Biagi J, Banashkevich A, et al. Management and outcomes of localized
esophageal and gastroesophageal junction cancer in older patients. Curr
Oncol. 2015;22:e435–42.
24. Servagi-Vernat S, Crehange G, Roullet et al. Phase II study of a platinum-based
adapted chemotherapy regimen combined with radiotherapy in patients 75
years and older with esophageal cancer. Drugs Aging 2015;32:487–493.
25. Vlacich G, Samson PP, Perkins SM, et al. Treatment utilization and outcomes
in elderly patients with locally advanced esophageal carcinoma: a review of
the National Cancer Database. Cancer Medicine. 2017;6:2886–96.
26. Voncken FE, van der Kaaij RT, Sikorska K, et al. Advanced age is not a
contraindication for treatment with curative intent in esophageal cancer.
Am J Clin Oncol. 2017; epub ahead of print
27. Häfner MF, Lang K, Krug D, et al. Prognostic factors, patterns of recurrence
and toxicity for patients with esophageal cancer undergoing definitive
radiotherapy or chemo-radiotherapy. J Radiat Res. 2015;56:742–9.
28. Nomura M, Shitara K, Kodaira T, et al. Recursive partitioning analysis for new
classification of patients with esophageal cancer treated by
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:786–92.
29. Xi M, Xu C, Liao Z, et al. The impact of histology on recurrence patterns in
esophageal cancer treated with definitive chemoradiotherapy. Radiother
Oncol. 2017;124:318–24.
30. Metzger JC, Wollschläger D, Miederer M, et al. Inclusion of PET-CT into
planning of primary or neoadjuvant chemoradiotherapy of esophageal
cancer improves prognosis. Strahlenther Onkol. 2017;193:791–9.
Walter et al. Radiation Oncology  (2018) 13:93 Page 11 of 12
31. Roeder F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy
(IMRT) with concurrent chemotherapy as definitive treatment of locally
advanced esophageal cancer. Radiat Oncol. 2014;9:191.
32. Freilich J, Hoffe SE, Almhanna K, et al. Comparative outcomes for three-
dimensional conformal versus intensity-modulated radiation therapy for
esophageal cancer. Dis Esophagus. 2015;28:352–7.
33. Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-
term outcomes with 3-dimenionals conformal radiotherapy vs intensity-
modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys.
2012;84:1078–85.
34. Wang X, Miao C, Chen Z, et al. Can involved-field irradiation replace elective
nodal irradiation in chemoradiotherapy for esophageal cancer ? A systematic
review and meta-analysis. Onco Targets Ther. 2017; epub ahead of print
35. Jing W, Zhu H, Guo H, et al. Feasibility of elective nodal irradiation (ENI) ad
involved field irradiation (IFI) in radiotherapy for the elderly patients (aged
≥ 70 years) with esophageal squamous cell cancer: a retrospective analysis
from a single institute. PLoS One. 2015;10(12):e0143007.
Walter et al. Radiation Oncology  (2018) 13:93 Page 12 of 12
